GSK Is First To Share Cancer Drug Patents With Poor Countries
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline to license its future cancer treatments for generic manufacturing in poor countries; access continues to be flagship issue for GSK's Witty, who also sits on recently formed UN access panel.
You may also be interested in...
More Pressure On Pharma: UN Report Backs Compulsory Licensing
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.